Renal Stone Risk Assessment
Clinical risk stratification for renal/ureteric stone recurrence to guide metabolic workup and prevention.
Score interpretation
Low stone recurrence risk
→ Fluid intake >2.5 L/day; dietary advice (moderate oxalate, normal calcium, low salt); GP follow-up
Moderate recurrence risk
→ 24-hour urine collection; serum calcium, uric acid, oxalate, citrate; dietary counselling; urology referral
High stone recurrence risk
→ Urgent urology/nephrology referral; full metabolic evaluation; pharmacotherapy (thiazides, allopurinol, citrate, cystine-specific agents); consider stone removal if residual
Interpretation bands for the Stone Risk. Apply clinical judgement and local guidance.
References
- EAU Guidelines on Urolithiasis. European Association of Urology. 2023.
Related
Curated clinical cross-links plus same-class fallbacks.
- Allopurinol · Xanthine Oxidase Inhibitor — Uric Acid Stone Prevention
- Diclofenac · NSAID — Renal / Ureteric Colic
- Anethol with Borneol, Camphene, Cineole, Fenchone and Pinene · Terpene Mixture (Urolithiasis / Renal Colic)
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Noradrenaline (Norepinephrine) · Vasopressor (Alpha-1 and Beta-1 Agonist)
- Tranexamic Acid (ICU/Trauma/Surgical) · Antifibrinolytic
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.